JW Holdings said it has initiated the full-scale export of Winuf Central 736/1,085ml, a three-chamber total parenteral nutrition (TPN), to Mongolia through local pharmaceutical firm AsiaPharma LLC. 

TPN refers to the feeding of nutritional products to a person intravenously, bypassing the usual process of eating and digestion. TPN is used when a person's digestive system does not work.

It is the first time that Winuf is being shipped to an Asian country.

Winuf, a three-chamber total parenteral nutrition (TPN) (Credit: JW Holdings)
Winuf, a three-chamber total parenteral nutrition (TPN) (Credit: JW Holdings)

JW Holdings, the global business arm of JW Group, inked an exclusive supply agreement with AsiaPharma in December 2021 for Winuf in the Mongolian market.

Established in 2002, AsiaPharma has been involved in the import and distribution of various medicines and medical devices for 21 years, JW Holdings said. 

AsiaPharma obtained a product license for Winuf from the Mongolian Ministry of Health in December 2022 and officially commenced local sales this month.

Winuf is a multi-nutrient fluid developed by JW Life Science, dividing a single container into three chambers to facilitate the mixing of nutrients such as refined fish oil, four types of lipids, amino acids, and glucose. 

The product has a higher content of omega-3 and omega-6 fatty acids compared to existing TPNs, JW Holdings said.

JW Pharmaceutical, another affiliate of JW Group,  distributes Winuf in Korea. The company has been leading the domestic TPN market since 2013. 

"As Winnuff takes its initial steps into Asian countries, we aim to further solidify our position as a global nutrition company by entering additional countries," said an official at JW Holdings. 

Meanwhile, JW Life Science, a subsidiary of JW Holdings, completed the expansion of TPN Line 3, Korea's first automated production facility for dedicated volume comprehensive nutritional fluids, at its fluid production plant in Dangjin, South Chungcheong Province, last October. 

With the full-scale operation of TPN Line 3, JW Life Sciences' maximum annual production of TPNs increased by 37 percent from 10.2 million to 14 million units. 

The company's total annual output of all fluids, including multivitamins, is 180 million units, the largest in Korea.

 

Copyright © KBR Unauthorized reproduction, redistribution prohibited